With adding mucoadhesive polymeric mixtures to the particles, the absolute bioavailability of the drug were found to increase from 70.1%to 97.9%.
微粒经肺部给药后的AUC_(0-480)不受微粒的可吸入粒子分布影响，通过添加粘膜黏附性高分子化合物后，药物的绝对生物利用从70.1%增加到了97.9%。
Results: The dynamic course of cetirizine plasma concentrations conformed to a two-compartment open model and the pharmacokinetic parameters after a single oral dose of 10mg domestic tablet and Zyrtec tablet were as follows: cmax were (316.71±39.66) and (314.80±31.79)ng/ml, t were(0.72±0.09) and (0.72±0.09)h, t(subscript 1/2β) were (10.71±3.06) and (9.95±2.41) h, AUC(subscript 0~∞) were (2728.52±356.06) and (2753.01±360.33)ngh/ml, respectively.
结果：盐酸西替利嗪的体内动态过程呈一级吸收的二房室开放模型，国产片和进口片的C分别为(316.71±39.66)和(314.80±31.79)ng/ml，t分别为(0.72±0.09)和(0.72±0.09) h，t(下标 1/2β)分别为(10.71±3.06)和(9.95±2.41) h，AUC(下标 0~∞)分别为(2728.52±356.06)和(2753.01±360.33)ngh/ml。
In different tissues such as heart, lung, muscle were determined resp. at 0.25, 0.50, 1.00, 2.00, 4.00h after administration. The gatifloxacin had good linear relation over the range from 0.05 to 5.00μg/ml, with a detection limit of 0.05μg/ml. The pharmacodynamics process of rabbits fitted to one compartment model. The main kinetic parameters for the dose groups at 5, 10, and 20 mg/kg were follows: C were 2.28, 3.35 and 7.93μg/ml reap. T were 1.36, 1.83 and 1.69 h reape.; t(subscript 1/2) Ka were 0.39, 0.51 and 0.42 h reap.; t(subscript 1/2)Ke were 5.63, 6.07 and 6.81 h reap.; AUC were 21.67, 33.59 and 97.07/ml reap.
结果］加替沙星在0.05~5.00μg/ml范围内具有良好线性关系，最低检测限为0.05μg/ml，在家兔血液代谢动力学过程符合一室模型。5、10和20mg/kg剂量组主要动力学参数如下：峰浓度C(下标 max分别为2.28、3.35和7.93μg/ml；达峰时间T(下标 max分别为1.36、183和1.69h；吸收半衰期t(下标 1/2Ka分别为0.39、0.51和0.42h；消除半衰期t(下标 1/2Ke分别为5.63、6.07和6.81h；药时曲线下面积分别为21.67、3359和97.07/ml。
AUC848 based MCU and DSP 5410 the HPI communications procedures and the use of MCU serial transmission to their PC...
基于单片机AUC848与DSP 5410的HPI通讯程序，并利用单片机的串口将其传送到上位机，实现DSP的数据采集功能。
The pharmacokinetics of biapenem was fitted in a twocompartment open model, the mean peak concentrations in serum was (16.64±3.32), (17.01±3.92)mg/L; the area under the concentration_timecurve was (27.28±8.94), (26.85±7.46)［mg/］; and the elimination halflife (t1/2β) being (1.17±0.69), (0.85±0.13) h, respectively.
受试者静注比阿培南单剂和多剂后体内过程均符合二房室模型，主要药动学参数cmax分别为(16.64±3.32)和(17.01±3.92)mg/L；平均AUC(0～∞)(27.28±8.94)和(26.85±7.46)［mg/］，平均血浆消除半衰期t1/2β分别为(1.17±0.69)和(0.85±0.14)h。
The influences of the composition of precipitant, stirring rate and supersaturation level on AUC crystal are studied.
研究了沉淀剂组成、搅拌速度、溶液的过饱和度等因素对AUC沉淀结晶的影响。
Whereas in the gray zone ranges of 4 to 10 ng/mL, the ROC-AUC for zinc was 70.5%(P.01) higher than 62.4% of f/t PSA ratio.
用100μg/ml作为血清锌的临界值，前列腺癌诊断的灵敏度和特异度分别为86%和53%，PSA在4~10ng/ml人群中分别为83%和53%。
ResultsThe fate of drug was consistent with finst order absorption and two compartement models (weight=1/CC), major kinetia parameters of pharmacokinetics and equation were as follows: T1/2ka=(45.29±2.07) min, T1/2a=(63.963±15.258) min, T1/2β=(280.535±214.601) min, Tmax=(50±17) min, Cmax=(14.905±3.143) mg/L, AUC(0～1440)=(2561.219±430.592)(mg·min-1·L-1), Ka=(0.015±0.001)(1/min), MRT(0～1440)=(196.865±50.656)min, C=66.697·e-0.011t+6.031·e-0.004t-72.728·
结果药物体内过程符合一级吸收二室模型（权重=1/CC），主要动力学参数及拟合方程如下：T1/2Ka为(45.294±2.07) min，T1/2α为(63.963±15.258)min，T1/2β为(280.535±214.601) min，Tmax为(50±17.321)min，Cmax为(14.905±3.143) mg/L，AUC(0-1440)为(2 561.219±430.592)(mg·min·L-1)，Ka为(0.015±0.001)min-1，MRT（0→1440）为（196.865±50.656）min，拟合方程为：C=66.697·e-0.011t+6.031·e-0.004t-72.728·
The limitation of MD technique wasobserved by investigating the drug release in vitro, the cutaneous absorption of drug invivo and the drug concentration in dermal tissue. Results:Ⅰ: The flow rate of probe was the most important factor among those influencefactors. There was a reverse exponential function correlation between relative recovery of probe and flow rate. The correlation between temperature and RR was linear. The drug concentration of medium had no influence on RR in the range of ourexperiment. The RRs were of no significant differentiation using different detectingmethods.Ⅱ: The total absorption (evaluated by AUCo.6)of lidocaine and prilocaine in theP-L formulation was significantly higher than those in EMLA with 2.32 times forlidocaine and 2.29 times for prilocaine.
结果Ⅰ：在微透析方法的众多影响因素中，探针的灌流速度对实验结果影响最大，探针的相对回收率与灌流速度之间存在反指数关系；回收率和温度之间呈线性正相关；在实验浓度范围内，探针回收率与周围溶液浓度无相关性；对实验样品雷公藤内酯醇而言，不同的回收率测定方法所得结果之间无显著性差异；Ⅱ：外用实验制剂P-L软膏后两主成分利多卡因和丙胺卡因的经皮吸收总量以AUC_(0-6为评价指标分别为EMLA的2.32和2.29倍，而皮内药物达峰浓度C_(max分别为EMLA的2.77和2.64倍。
Plasma concentrations of-enantiomer were found always greater than those of-enantiomer, the ratios of/-enantiomer for AUC and Cmax were 1.589±0.201, 1.458±0.228, respectively, which showed the metabolic enantioselectivity of OPZ.
奥美拉唑omeprazole，OPZ）的化学结构为5-甲氧基-2-［［(4-甲氧基-3，5-二甲基-2-吡啶甲基］亚砜］-1H-苯骈咪唑，它能选择性地抑制胃壁上H+，K+-ATP酶的活性，减少胃酸分泌，临床上用于治疗由胃酸分泌过多引起的胃肠道紊乱疾病〔1〕。
The elimination half-lives(T1/2β) were 0.69 ± 0.31, 0.73 ±0.16, 0.55 ±0.07和 0.84±0.32h, the area under curves(AUC0-T) were 11.76±2.78, 30.82±7.75, 61.04±6.54和 153.31 ±60.49 mg/L*h, respectively. The area under curves(AUC0-T) were linearly related to the dosages (r=0.9961, P.05). Mean residence time (MRT0-tn) of four dosages was 0.76±0.12, 0.84±0.150.75±0.08 和 0.84±0.14h by noncompartmental analyses, respectively.
其房室模型参数T_(1/2β)分别为0.69±0.31、0.73±0.16、0.55±0.07和0.84±0.32，AUC_(0-T)分别为11.76±2.78、30.82±7.75、61.04±6.54和153.31±60.49；AUC_(0-t)与4个给药剂量之间的线性相关系数r等于0.9961(P＜0.05)；统计矩参数MRT_(0-tn分别为0.76±0.12、0.84±0.15、0.75±0.08和0.84±0.14。
The main pharmacokinetic parameters of Hui and Han group were as follows: t(subscript 1/2)(6.8 ± s 1.0) and (6.2 ± 10) h, t (2.6 ± 0.7) awl (2.4 ± 0.7) h, ρ(309 ± 55) and (401 ± 78)μgL^(-1), AUC(subscript 0-36)(3483±799) and (4297±1262)μghL^(-1), AUC(subscript 0-∞)(3613±862) and (4456±1318)μghL^(-1), V1/F (3.6 ± 0.6) and (5.0 ± 0.9) Lkg^(-1), respectively.
主要药动学参数分别为，t(下标 1/2)：(6.8±s1.0)和(6.2±1.0)h，t：(2.6±0.7)和(2.4±0.7)h，ρ：(309±55)和(401±78)μgL^(-1)，AUC(下标 0-36)：(3483±799)和(4297±1262)μghL^(-1)，AUC(下标 0-∞)：(3613±862)和(4456±1318)μghL^(-1)，V1/F：(3.6±0.6)和(5.0±0.9)Lkg^(-1)。汉族、回族受试者ρ、AUC(下标 0-4)、和AUC(下标 0-∞)个体间差异较大。
Methods 12 anesthesia dogs were randomly divided into two groups of control group and QDTMT treatment group: the animal was anesthetized and the left anterior descending coronary artery of open-chest animal was isolated for measuring blood flow with an electromagnetic flow probe, then the animal was subjected to 90min of LAD occlusion followed by 180min reperfusion after 30min of administrating saline in control.
应用12只健康犬，随机分为对照组和芪丹通脉片治疗组，对照组经十二指肠给予生理盐水(1.5ml/kg)，给药后30min分离冠状动脉左前降支，放置电磁流量计探头测定血流量，在其下缘左前降支l/2处结扎90min，松开后再灌注180min观察，分别于灌胃前、缺血90min和再灌注180min静脉快速均匀推入微泡声学造影剂SONOVUE，FLASH模式进行静脉声学造影，实时连续记录心肌声学造影前后的图像采用，采用Echopac图象工作站软件包进行分析心肌声学造影的图像视频密度，根据时间－视频密度曲线计算曲线下面积(area under curve，AUC)以评价心肌微血管的血流灌注状态，根据图像分析缺血心肌范围的影响。
Insulin AUC and HOMA-IR were higher in hyperlipidemic rat than in the controt rat. GLP-1R relative mRNA level was lower in the hyperlipidemic rat than in the control rat.
高脂大鼠胰岛素曲线下面积和胰岛素抵抗指数高于对照大鼠，高脂大鼠卵巢GLP-1R mRNA相对表达量低于对照大鼠，为对照大鼠的63%。
The pharmacokinetic parameters of the reference and test formulations were(4.60±2.43)and(4.85±2.30)mg·L -1 for c max; (19.56±10.24) and (19.28±9.43) mg·h·L -1 for AUC 0→24; (3.57±1.5) and (3.15±1.2)h for T 1/2; (1.2±0.4) and (1.3±0.5)h for t max respectively.
参比制剂和受试制剂的主要药动学参数cmax分别为(4.6 0±2 。4 3)和(4.85±2 。30)mg·L-1，AUC0→2 4为(19.5 6±10 。2 4)和(19.2 8±9.4 3)mg·h·L-1，T1/ 2 为(3.5 7±1.5)和(3.15±1.2)h ；tmax为(1.2±0 。4)和(1.3±0 。5)h。
The method of HPLC was emphasizedly employed to compare the pharmacokinetics of 5-FU-CH and 5-FU-H20 formulation after their administration in the obdominal cavity of naked mice suffering from ascites cancer. The results demonstrated that AUC of 5-FU-CH formulation was smaller than that of 5-FU-H20, proving that drug concentration in prepheral plasma was more lower than that of 5-FU-H20 formulation. All of this indicated that this formulation was more detained locally on the focus site of obdominal cavity than 5-FU-H20 formulation.
为600mg八g，5－FU－H.0的为Z16ms／ks；并用高效液相色谱法进行了 5－FU－CH制剂与5－FU－H.0制剂分别腹腔投予腹水癌模型裸鼠的初步药动学比较研究，结果表明，5－FU－CH制剂的AUC小于5－FU－H.0制剂，证明该制剂在外周血浆中浓度低于5－FU－Hzo制剂，提示该制剂在病灶部位腹腔的局部滞留性高于5－FU－H.0制剂。
A sensitive and specific HPLC method was developed to quantitate the levels of canrenone in plasma, which was the metabolite of spironolactone.
结果：参比制剂和受试制剂药-时曲线均符合一房室模型，受试制剂和参比制剂的代谢物坎利酮的药动学参数如下：t_分别为(4.2±s 1.2)和(4.7±1.6)h，C_分别为(160±47)和(150±43)μg·L~(-1)，t_(1/2ke)分别为(18±5)和(19±4)h，AUC_(0～72)分别为(3168±688)和(3267±627)μg·h·L~(-1)，AUC_(0～∞)分别为(3611±768)和(3759±642)μg·h·L~(1-)。
The plasma concentra- tions of acrivastine were determined by HPLC. The pharmacokinetic parameters and relative bioequivalence were calculated with 3P97 program.
结果：受试制剂与参比制剂的药-时曲线呈二室模型，t_分别为(1.0±s 0.4)h和(1.1±0.4)h；c_分别为(220±64)μg·L~(-1)和(220±84)μg·L~(-1)；AUC_(0～1)分别为(626±276)μg·h·L~(-1)和(650±271)μg·h·L~(-1)；t_(12β)分别为(1.9±2.3)h和(1.9±1.5)h，2种制剂的主要药动学参数无显著差异(P＞0.05)，受试制剂的相对生物利用度为(97±12)％。
Miltiorrhiza depside salts in beagle dogs, the high AUC was obtained for LSB with a steady high concentration in blood during the infusion. 3. Pharmacokinetics of S.
静脉滴注丹参多酚酸盐的给药方式下，丹参乙酸的药时曲线下面积明显高于同剂量下静脉注射或皮下注射方式的AUC，丹参乙酸在滴注给药期间维持稳定的峰浓度。
At the IV dose of 20 and 30 mg/kg, Aloin and Isobarbaloin result appear the mean terminal eliminate half-life（T1/2 β）were 54.1±28.4; 28.7±18.3 and 36.9±21.9; 49.7±17.1 min, respectively. The mean area under the serum concentration curve（AUC0-∞）were about 411.655± 13.027; 318.213±19.924 and 701.336±116.631; 573.278± 86.870μg min/mL, respectively. The mean drug clearancewere 0.165±0.011; 0.214±0.016 and 0.149±0.030; 0.182±0.035 L/min, respectively.
若静脉注射剂量20和30 mg/kg后，其芦荟大黄苷及异芦荟大黄苷分别平均末端排除半衰期（T1/2 β）为54.1±28.4；28.7±18.3和36.9±21.9；49.7±17.1 min，平均稳定状态分布体积为7.668±3.155；6.343±3.522和5.146±2.490；8.525±2.683 L，平均曲线下面积（AUC0-∞）为411.655 ±13.027；318.213±19.924 和701.336±116.631；573.278±86.870 μgmin/mL，平均血浆中药物最高浓度为23.920±5.669；30.442 ±7.537和57.920±27.690；36.373±14.174 μg/mL，平均药物之清除率为0.165±0.011；0.214±0.016和0.149±0.030；0.182±0.035 L/min。